Alnylam Pharmaceuticals/$ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Ticker
$ALNY
Sector
Primary listing
Employees
2,230
Headquarters
Website
ALNY Metrics
BasicAdvanced
$60B
-
-$2.46
0.22
-
Price and volume
Market cap
$60B
Beta
0.22
52-week high
$484.21
52-week low
$205.87
Average daily volume
1.1M
Financial strength
Current ratio
2.801
Quick ratio
2.633
Long term debt to equity
1,035.997
Total debt to equity
1,093.309
Interest coverage (TTM)
-1.18%
Profitability
EBITDA (TTM)
-123.687
Gross margin (TTM)
83.64%
Net profit margin (TTM)
-12.96%
Operating margin (TTM)
-7.32%
Effective tax rate (TTM)
15.94%
Revenue per employee (TTM)
$1,100,000
Management effectiveness
Return on assets (TTM)
-2.63%
Return on equity (TTM)
-257.82%
Valuation
Price to revenue (TTM)
24.176
Price to book
240.21
Price to tangible book (TTM)
240.21
Price to free cash flow (TTM)
-1,142.697
Free cash flow yield (TTM)
-0.09%
Free cash flow per share (TTM)
-0.402
Growth
Revenue change (TTM)
5.01%
Earnings per share change (TTM)
325.37%
3-year revenue growth (CAGR)
40.68%
10-year revenue growth (CAGR)
44.46%
3-year earnings per share growth (CAGR)
-32.94%
10-year earnings per share growth (CAGR)
0.47%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
Bulls say / Bears say
The FDA’s March 20, 2025 approval of Amvuttra for ATTR-CM strengthens Alnylam’s leadership in RNAi therapies and unlocks an $11 billion market, with peak sales projected to reach $5 billion by 2029 (Reuters).
In Q2 2025, Alnylam reported $672 million in net product revenues, a 64% year-over-year increase fuelled by its TTR franchise, and raised its full-year forecast by 27% to $2.65–2.80 billion, showing strong commercial momentum (Nasdaq).
Royalty revenue soared 78.5% year-over-year to $39.98 million in Q2 2025, thanks to strong Leqvio uptake under the Novartis partnership, diversifying Alnylam’s revenue streams (Nasdaq).
Collaboration revenues dropped 73% year-over-year to $61.5 million in Q2 2025, mainly due to the lack of significant milestone payments, highlighting the unpredictability of Alnylam’s non-product income streams (Nasdaq).
Amvuttra is up against strong competition from Pfizer’s Vyndaqel in the ATTR-CM market, which is forecast to reach $11 billion by 2032, potentially restricting Alnylam’s market share and pricing flexibility (Reuters).
Amvuttra’s list price of $119,351 per injection may lead to resistance from insurers and reduce patient access, particularly given growing efforts to control specialty drug costs (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
ALNY News
AllArticlesVideos
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Business Wire1 week ago
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
Business Wire4 weeks ago
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $60B as of October 08, 2025.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of October 08, 2025.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.